Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

JOHN AINSLIE THOMPSON

Allopathic & Osteopathic Physicians Internal Medicine Medical Oncology

NPI
1447328539
CMS profile
337607
Location
SEATTLE, WA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2023 · Entire year

$175.78

2 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2023 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $175.78 2

By paying entity

PY2023 · entire year · sorted by reported total

Paying entityAmountRecords
Foundation Medicine, Inc. $135.78 1
Merck Sharp & Dohme LLC $40.00 1

Page 1 of 1; records 1–2 of 2 matching records. This page contains 2 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

JOHN AINSLIE THOMPSON

NPI 1447328539 · CMS profile ID 337607

Allopathic & Osteopathic Physicians / Internal Medicine / Medical Oncology

SEATTLE, WA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 1; records 1–2 of 2 matching records. This page contains 2 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1447328539?year=2023&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
JOHN AINSLIE THOMPSON, NPI 1447328539, CMS profile ID 337607. General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–2 of 2 matching records. This page contains 2 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1447328539?year=2023&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9.
APA 7
IndustryPayments. (2026). JOHN AINSLIE THOMPSON, NPI 1447328539, CMS profile ID 337607. General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–2 of 2 matching records. This page contains 2 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1447328539?year=2023&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9.
Bluebook
JOHN AINSLIE THOMPSON, NPI 1447328539, CMS profile ID 337607, IndustryPayments, General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–2 of 2 matching records. This page contains 2 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9. https://industrypayments.org/provider/npi-1447328539?year=2023&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2023

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2023 · Physicians and non-physician practitioners · CMS publication 2026-06-30

2 matching records · $175.78 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 2 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–2 of 2.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Foundation Medicine, Inc. $135.7807/04/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1061092207 CMS
Merck Sharp & Dohme LLC $40.0003/31/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1048265615 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $2,392.67 5
PY2021 $8,116.48 5
PY2022 $717.00 14
PY2023 $175.78 2
PY2024 $663.57 6

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2021, 2022, 2023, 2024
Source files and profile matching
Source files
Dataset page · Bulk file · PY2019 , PY2021 , PY2022 , PY2023 , PY2024
Generated from
OP_DTL_GNRL_PGYR2024_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2024 Principal investigator $31,520.00 1
PY2023 Principal investigator $39,453.02 12
PY2022 Recipient $3,200.00 1
PY2022 Principal investigator $83,048.98 13
PY2021 Recipient $1,400.00 1
PY2021 Principal investigator $574,171.33 20
PY2020 Recipient $3,200.00 1
PY2020 Principal investigator $664,597.14 33
PY2019 Principal investigator $943,108.29 79

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2021

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

21 records in PY2021

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Merck Sharp & Dohme Corporation $3,765.60 12/31/2021 Non-covered Recipient Entity
Seattle Cancer Care Alliance
A Phase I,II clinical trial to study the safety and tolerability of MK-3475 Pegylated Interferon alfa-2b PEG-IFN and MK-3475 Ipilimumab IPI in Subjects with Advanced Melanoma MEL and Renal Cell Carcinoma RCC No dispute reported 06/30/2026 848743177
Principal investigator 1 Gilead Sciences, Inc. $30,294.00 11/15/2021 Covered Recipient Teaching Hospital
University Of Washington Med Ctr
A Phase 1b Dose Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of GS 3583, a FLT3 agonist Fc fusion protein, in Subjects with Advanced Solid Tumors No dispute reported 06/30/2026 803523001
Principal investigator 1 PFIZER INC. $24,389.13 11/05/2021 Covered Recipient Teaching Hospital
UNIVERSITY OF WASHINGTON MED CTR
A PHASE 1 STUDY TO EVALUATE THE SAFETY PHARMACOKINETICS AND PHARMACODYNAMICS OF ESCALATING DOSES OF PF06940434 IN PATIENTS WITH ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 832836335
Principal investigator 1 PFIZER INC. $2,760.45 11/04/2021 Covered Recipient Teaching Hospital
UNIVERSITY OF WASHINGTON MED CTR
A PHASE 1 DOSE ESCALATION AND EXPANSION STUDY TO EVALUATE SAFETY TOLERABILITY PHARMACOKINETIC PHARMACODYNAMIC AND ANTITUMOR ACTIVITY OF PF07209960 IN PARTICIPANTS WITH ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 832879927
Principal investigator 1 PFIZER INC. $14,739.62 09/21/2021 Covered Recipient Teaching Hospital
UNIVERSITY OF WASHINGTON MED CTR
A PHASE 1 DOSE ESCALATION AND EXPANSION STUDY TO EVALUATE SAFETY TOLERABILITY PHARMACOKINETIC PHARMACODYNAMIC AND ANTITUMOR ACTIVITY OF PF07209960 IN PARTICIPANTS WITH ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 832758929
Principal investigator 1 PFIZER INC. $2,650.28 09/21/2021 Covered Recipient Teaching Hospital
UNIVERSITY OF WASHINGTON MED CTR
A PHASE 1 STUDY TO EVALUATE THE SAFETY PHARMACOKINETICS AND PHARMACODYNAMICS OF ESCALATING DOSES OF PF06940434 IN PATIENTS WITH ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 832784583
Principal investigator 1 PFIZER INC. $17,118.00 09/03/2021 Covered Recipient Teaching Hospital
UNIVERSITY OF WASHINGTON MED CTR
A PHASE 1 DOSE ESCALATION AND EXPANSION STUDY TO EVALUATE SAFETY TOLERABILITY PHARMACOKINETIC PHARMACODYNAMIC AND ANTITUMOR ACTIVITY OF PF07209960 IN PARTICIPANTS WITH ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 832720485
Principal investigator 1 PFIZER INC. $3,003.00 07/20/2021 Covered Recipient Teaching Hospital
UNIVERSITY OF WASHINGTON MED CTR
A PHASE 1 DOSE ESCALATION AND EXPANSION STUDY TO EVALUATE SAFETY TOLERABILITY PHARMACOKINETIC PHARMACODYNAMIC AND ANTITUMOR ACTIVITY OF PF07209960 IN PARTICIPANTS WITH ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 832798341
Principal investigator 1 PFIZER INC. $994.00 07/01/2021 Covered Recipient Teaching Hospital
UNIVERSITY OF WASHINGTON MED CTR
A PHASE 1 STUDY TO EVALUATE THE SAFETY PHARMACOKINETICS AND PHARMACODYNAMICS OF ESCALATING DOSES OF PF06940434 IN PATIENTS WITH ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 832899897
Principal investigator 1 Merck Sharp & Dohme Corporation $5,198.34 06/14/2021 Covered Recipient Teaching Hospital
UNIVERSITY OF WASHINGTON MED CTR
A Phase I,II clinical trial to study the safety and tolerability of MK-3475 Pegylated Interferon alfa-2b PEG-IFN and MK-3475 Ipilimumab IPI in Subjects with Advanced Melanoma MEL and Renal Cell Carcinoma RCC No dispute reported 06/30/2026 848743175
Principal investigator 1 PFIZER INC. $9,435.03 05/21/2021 Covered Recipient Teaching Hospital
UNIVERSITY OF WASHINGTON MED CTR
A PHASE 1 STUDY TO EVALUATE THE SAFETY PHARMACOKINETICS AND PHARMACODYNAMICS OF ESCALATING DOSES OF PF06940434 IN PATIENTS WITH ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 832898983
Principal investigator 1 PFIZER INC. $15,097.24 05/06/2021 Covered Recipient Teaching Hospital
UNIVERSITY OF WASHINGTON MED CTR
A PHASE 1 STUDY TO EVALUATE THE SAFETY PHARMACOKINETICS AND PHARMACODYNAMICS OF ESCALATING DOSES OF PF06940434 IN PATIENTS WITH ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 832781091
Principal investigator 1 PFIZER INC. $309.33 03/24/2021 Covered Recipient Teaching Hospital
UNIVERSITY OF WASHINGTON MED CTR
A PHASE 1 OPENLABEL DOSE ESCALATION STUDY OF PF04518600 AS A SINGLE AGENT AND IN COMBINATION WITH PF05082566 IN PATIENTS WITH SELECTED LOCALLY ADVANCED OR METASTATIC CANCERS No dispute reported 06/30/2026 832789113
Principal investigator 1 PFIZER INC. $27,682.03 03/24/2021 Covered Recipient Teaching Hospital
UNIVERSITY OF WASHINGTON MED CTR
A PHASE 1 OPENLABEL DOSE ESCALATION STUDY OF PF04518600 AS A SINGLE AGENT AND IN COMBINATION WITH PF05082566 IN PATIENTS WITH SELECTED LOCALLY ADVANCED OR METASTATIC CANCERS No dispute reported 06/30/2026 832908683
Principal investigator 1 PFIZER INC. $2,337.00 03/20/2021 Covered Recipient Teaching Hospital
UNIVERSITY OF WASHINGTON MED CTR
A PHASE 1 STUDY TO EVALUATE THE SAFETY PHARMACOKINETICS AND PHARMACODYNAMICS OF ESCALATING DOSES OF PF06940434 IN PATIENTS WITH ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 832836491
Recipient PFIZER INC. $1,400.00 03/05/2021 Covered Recipient Physician ONCOLOGY PORTFOLIO CLINICAL PUBLICATION PROGRAM No dispute reported 06/30/2026 832503875
Principal investigator 1 PFIZER INC. $2,817.50 03/03/2021 Covered Recipient Teaching Hospital
UNIVERSITY OF WASHINGTON MED CTR
A PHASE 1 OPENLABEL DOSE ESCALATION STUDY OF PF04518600 AS A SINGLE AGENT AND IN COMBINATION WITH PF05082566 IN PATIENTS WITH SELECTED LOCALLY ADVANCED OR METASTATIC CANCERS No dispute reported 06/30/2026 832854465
Principal investigator 1 PFIZER INC. $5,554.99 02/20/2021 Covered Recipient Teaching Hospital
UNIVERSITY OF WASHINGTON MED CTR
A PHASE 1 STUDY TO EVALUATE THE SAFETY PHARMACOKINETICS AND PHARMACODYNAMICS OF ESCALATING DOSES OF PF06940434 IN PATIENTS WITH ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 832820095
Principal investigator 1 Novartis Pharmaceuticals Corporation $311,081.18 01/19/2021 Covered Recipient Teaching Hospital
UNIVERSITY OF WASHINGTON MED CTR
A PHASE I IB STUDY OF SUBCUTANEOUS RECOMBINANT HUMAN NIZ985 ALONE AND IN COMBINATION WITH PDR001 IN ADULTS WITH METASTATIC CANCERS No dispute reported 06/30/2026 800618157
Principal investigator 1 PFIZER INC. $70,965.79 01/15/2021 Covered Recipient Teaching Hospital
UNIVERSITY OF WASHINGTON MED CTR
A PHASE 1 STUDY TO EVALUATE THE SAFETY PHARMACOKINETICS AND PHARMACODYNAMICS OF ESCALATING DOSES OF PF06940434 IN PATIENTS WITH ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 832898977
Principal investigator 1 PFIZER INC. $23,978.82 01/09/2021 Covered Recipient Teaching Hospital
UNIVERSITY OF WASHINGTON MED CTR
A PHASE 1 STUDY TO EVALUATE THE SAFETY PHARMACOKINETICS AND PHARMACODYNAMICS OF ESCALATING DOSES OF PF06940434 IN PATIENTS WITH ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 832788445